David Enright, M.D.; Decision and Order
DEA revoked Dr. David Enright's registration for egregious controlled substance prescribing, signaling increased scrutiny on individual practitioners and pharmacies filling suspicious orders.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies should confirm how it applies to their specific situation before acting. There is a time constraint attached: Within 30 days. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
DEA revoked Dr. Enright's registration for failing to maintain effective controls against diversion, including prescribing outside usual course of practice and failing to report theft/loss. This sets a precedent for enforcement against prescribers and pharmacies that fill such orders.
Who it affects
Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies
What you must do
Review and strengthen suspicious order monitoring programs; ensure policies for reporting suspicious activity to DEA; train staff on red flags for diversion.
Deadline
Within 30 days
Source: https://www.federalregister.gov/documents/2026/07/14/2026-14135/david-enright-md-decision-and-order
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
- Amanda Ward, N.D.; Decision and Order